AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Ernexa Therapeutics Inc. Director's Dealing 2021

Apr 5, 2021

35259_dirs_2021-04-05_878d9861-61ce-4b35-8c94-1ba85189682a.zip

Director's Dealing

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Brooklyn ImmunoTherapeutics, Inc. (BTX)
CIK: 0000748592
Period of Report: 2021-03-25

Reporting Person: Mason Lynn Sadowski (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	94333	Direct